Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling-Reference-Cited by-同舟云学术

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

Published:2019-05-09 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Di Benedetto Paola^ORCID,Panzera Noemi,Cipriani Paola,Mastroiaco Valentina,Tessitore Alessandra,Liakouli Vasiliki,Ruscitti Piero,Berardicurti Onorina,Carubbi Francesco,Guggino Giuliana,Bianchi Andrea,Di Marco Antinisca^ORCID,Ciccia Francesco,Alesse Edoardo,Giacomelli Roberto

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-43638-0.pdf

Reference60 articles.

1. Altorok, N., Wang, Y. & Kahaleh, B. Endothelial dysfunction in systemic sclerosis. Curr Opin Rheumatol. 26, 615–620 (2014).

2. Cipriani, P. et al. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. J Rheumatol. 42, 1808–1816 (2015).

3. Cipriani, P. et al. Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features. Arthritis Res Ther. 16, 442 (2014).

4. Di Benedetto, P. et al. Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Res Ther. 20, 223 (2018).

5. Cipriani, P. et al. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 17, 247 (2015).

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases—systemic sclerosis and sclerodermatous graft-versus-host disease;Stem Cell Research & Therapy;2023-12-18

2. Adipose Tissue and Adipose-Tissue-Derived Cell Therapies for the Treatment of the Face and Hands of Patients Suffering from Systemic Sclerosis;Biomedicines;2023-01-26

3. Immunopathogenesis and treatment of scleroderma;Translational Autoimmunity;2023

4. Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches;Cells;2022-10-24

5. Cell Based Treatment of Autoimmune Diseases in Children;Frontiers in Pediatrics;2022-05-09